Yahoo
    TSXV - Delayed Quote CAD

    NurExone Biologic Inc. (NRX.V)

    0.4800 -0.0200 (-4.00%)
    At close: November 4 at 3:49:57 PM EST
    Loading Chart for NRX.V
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    NurExone Demonstrates Consistent Anti-Inflammatory Activity Across Three Separate Batches of Exosomes

    NurExone Demonstrates Consistent Anti-Inflammatory Activity Across Three Separate Batches of Exosomes
    GlobeNewswire 5d ago
    NurExone Demonstrates Scalable Exosome Production, Supporting Its Modular Manufacturing Strategy and Commercial Growth

    NurExone Demonstrates Scalable Exosome Production, Supporting Its Modular Manufacturing Strategy and Commercial Growth
    GlobeNewswire 13d ago
    NurExone Advances Optic Nerve Injury Program Toward Larger-Animal Study, Following Positive Preclinical Results

    NurExone Advances Optic Nerve Injury Program Toward Larger-Animal Study, Following Positive Preclinical Results
    GlobeNewswire 26d ago
    NurExone Expands U.S. Engagement Across Four Major Boston Life Sciences Events and Provides Corporate Update

    NurExone Expands U.S. Engagement Across Four Major Boston Life Sciences Events and Provides Corporate Update
    GlobeNewswire 1mo ago
    NurExone Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update

    NurExone Announces Voting Results of Annual General and Special Meeting of Shareholders and Provides Corporate Update
    GlobeNewswire 1mo ago
    NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications

    NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications
    GlobeNewswire 1mo ago
    NurExone Biologic progresses towards a new regenerative therapy and sets sights on a potential NASDAQ listing

    NurExone Biologic progresses towards a new regenerative therapy and sets sights on a potential NASDAQ listing
    InvestorsHub 2mo ago
    NurExone Biologic Inc. Announces Second Quarter 2026 Financial Results

    NurExone Biologic Inc. Announces Second Quarter 2026 Financial Results
    GlobeNewswire 2mo ago
    NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference

    NurExone Biologic Inc. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference
    GlobeNewswire 2mo ago
    NurExone Announces Annual General and Special Meeting to Consider Share Consolidation in Support of U.S. Capital Markets Strategy

    NurExone Announces Annual General and Special Meeting to Consider Share Consolidation in Support of U.S. Capital Markets Strategy
    GlobeNewswire 2mo ago
    NurExone Announces Binding MOU with Made Scientific for U.S. GMP Manufacturing and Commercial Supply Partnership

    NurExone Announces Binding MOU with Made Scientific for U.S. GMP Manufacturing and Commercial Supply Partnership
    GlobeNewswire 2mo ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: